
Vælg din etiket
vises direkte på hætteglassetReta + Cagri Blend
GLP-1
- Sendes fra Tyskland
Bestilling
- DHL med sporing
- Diskret emballage
Kort fortalt
Reta + Cagri Blend i tal
Nøgletallene fra vores leksikon.
Hele leksikonopslaget- Class
- Triple agonistGLP-1 / GIP / glucagon, + amylin analog
- Half-life
- Retatrutide around 6 dayscagrilintide around 7 to 8 days
- Form
- Lyophilisatepowder, reconstituted with BAC water
- Sizes
- 30 mg1 size in the shop
What studies show
All 5 sources in the lexicon- up to24.2 %Jastreboff et al., NEJM, 2023
- Sanyal et al., Nature Medicine, 2024
- Lau et al., The Lancet, 2021
Anmeldelser
Hvad kunderne siger
Kun rigtige bestillinger, der indeholdt Reta + Cagri Blend.
Alle anmeldelserDer er endnu ingen laboratorieanalyse for Reta + Cagri Blend. Stem på denFå det testet selv, vi betaler halvdelenAlle laboratorieanalyser
Viden
Alt om Reta + Cagri Blend
Detaljerede oplysninger kommer snart.
Dosering
Indlæser doseringsinformation …
Godt at have
Det har du brug for til den
Bakteriostatisk vand lægges automatisk i din kurv. Sprøjter og servietter med ét klik.
Insulinsprøjter
10 stk. · 5.50 €
Spritservietter
50 stk. · 10 €
Hvor meget vand?
Enheder på sprøjten til din hætteglasstørrelse.
Åbn beregneren →Is the Reta + Cagri Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.
Why Retatrutide and cagrilintide together?
Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.
What do the studies of the components show?
Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.
Why is the cagrilintide share so small?
The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.
How long do the components stay in the body?
Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.
Which side effects were seen with the components?
With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.
Relateret
Relaterede produkter
Tirzepatide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
10 størrelser
Laboratorietestet
= fra 10 €/hætteglas
Retatrutide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
11 størrelser
Laboratorietestet
= fra 16 €/hætteglas
Semaglutide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
6 størrelser
Laboratorietestet
= fra 10 €/hætteglas
Mazdutide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
2 størrelser
= fra 32 €/hætteglas
Reta + Cagri Blend